King's Board Cashing In On $3.6B Pfizer Deal: Suit
King Pharmaceuticals Inc. is facing a putative class action from shareholders who say the company's $3.6 million sale to Pfizer Inc. is a bid to cash in on its strong development...To view the full article, register now.
Already a subscriber? Click here to view full article